Volume 4.28 | Jul 26

Prostate Cell News 4.28 July 26, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4-STAT3 Signaling
The authors report that persistent co-culturing of immortalized prostate epithelial cells with macrophages, without adding any carcinogens, induces prostate tumorigenesis, and that induction involves the alteration of signaling of macrophage androgen receptor-inflammatory chemokine CCL4-STAT3 activation as well as epithelial-to-mesenchymal transition and down-regulation of p53/PTEN tumor suppressors. [Cancer Res]
Abstract | Full Article
Detect 7 times more prostate epithelial progenitors with ProstaCult
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Targeting Prostate Cancer Cell Lines with Polo-Like Kinase 1 Inhibitors as a Single Agent and in Combination with Histone Deacetylase Inhibitors
Scientists studied the effect of polo-like kinase 1 inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase inhibitors valproic acid and vorinostat. [FASEB J] Abstract

Hypoxia Enhances the Expression of Prostate-Specific Antigen by Modifying the Quantity and Catalytic Activity of Jumonji C Domain-Containing Histone Demethylases
Scientists showed that pathological hypoxia increased the expression of androgen receptor target genes such as prostate-specific antigen and kallikrein-related peptidase 2 in LNCaP human prostate cancer cells by modifying the quantity and activity of related Jumonji C domain-containing histone demethylases. [Carcinogenesis] Abstract

Peroxiredoxin-3 Is Overexpressed in Prostate Cancer and Promotes Cancer Cell Survival by Protecting Cells from Oxidative Stress
Peroxiredoxin-3 (PRDX-3) is upregulated in a number of endocrine-regulated tumors; in particular in prostate cancer and prostatic intraepithelial neoplasia. Although the majority of PRDX-3 is localised to the mitochondria, researchers confirmed that PRDX-3 at the cell membrane is androgen regulated. [Brit J Cancer] Abstract

Characterizations of Human Prostate Stem Cells Reveal Deficiency in Class I UGT Enzymes as a Novel Mechanism for Castration-Resistant Prostate Cancer
A deficiency in class 1 UDP glucuronosyltransferase (UGT) enzymes was identified in prostate stem cells (SCs), which are involved in androgen catabolism. Class 1 UGT enzyme expression was also downregulated in cancer SCs and during progression to metastatic castration-resistant prostate cancer. [Brit J Cancer] Abstract

CCR1/CCL5 Interaction Promotes Invasion of Taxane-Resistant PC3 Prostate Cancer Cells by Increasing Secretion of MMPs 2/9 and by Activating ERK and Rac Signaling
Researchers investigated the role of the chemokine receptor 1 (CCR1) and its ligand, chemokine ligand 5 (CCL5), in taxane-resistant castration-refractory prostate cancer using paclitaxel-resistant prostate cancer cells established from PC3 cells. [Cytokine] Abstract

Ghrelin O-acyltransferase (GOAT) Is Expressed in Prostate Cancer Tissues and Cell Lines and Expression Is Differentially Regulated In Vitro by Ghrelin
Scientists demonstrated that GOAT mRNA and protein are expressed in the normal prostate and human prostate cancer tissue samples. The RWPE-1 and RWPE-2 normal prostate-derived cell lines and the LNCaP, DU145, and PC3 prostate cancer cell lines express GOAT and at least one other enzyme that is necessary to produce mature, acylated ghrelin from proghrelin. [Reprod Biol Endocrinol] Abstract

Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated from Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors
Researchers report the establishment of long-term self-renewing prostate cancer stem cells lines from the different stages of transgenic adenocarcinoma of the mouse prostate progression by application of the neurosphere assay. [Stem Cells Transl Med] Abstract

Functional Activation of ATM by the Prostate Cancer Suppressor NKX3.1
NKX3.1 and ataxia telangiectasia mutated (ATM) have a functional interaction leading to ATM activation and then NKX3.1 degradation in a tightly regulated DNA damage response specific to prostate epithelial cells. [Cell Rep] Abstract | Graphical Abstract | Full Article

CLINICAL RESEARCH

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The authors assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. [N Engl J Med] Full Article | Press Release

Vaccination of Castration-Resistant Prostate Cancer Patients with TroVax (MVA–5T4) in Combination with Docetaxel: A Randomized Phase II Trial
Researchers report results from a randomized open-label Phase II trial in castration-resistant prostate cancer patients in which TroVax was administered in combination with docetaxel and compared against docetaxel alone. [Cancer Immunol Immunother] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
REVIEWS
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
A treatment paradigm of comprehensive androgen receptor (AR) axis targeting at multiple levels and at all relevant sites simultaneously at the time of initiation of endocrine therapy deserves examination in clinical trials to explore whether maximal first-line AR axis suppression via combination therapy can achieve maximal induction of cancer cell apoptosis and thus, improve patient outcomes. [Cancer Res] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Takeda Announces Unblinding of Phase III Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer that Progressed Post-Chemotherapy Based on Interim Analysis
Takeda Pharmaceutical Company Limited announced that it has unblinded the ELM-PC 5 Phase III study of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee. [Takeda Pharmaceutical Company Limited] Press Release

Brian Urban Selected as Cigna 2013 Volunteer of the Year
Brian Urban, a health educator and case management specialist from Baldwin, Penn., has been named Cigna’s Volunteer of the Year for his work with the Obediah Cole Prostate Cancer Foundation in Pittsburgh, Penn. [Cigna] Press Release

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2013 Australian-Canadian Prostate Cancer Research Alliance Symposium
August 14-17, 2013
Port Douglas, Australia

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Steroid Receptor Signaling (Baylor College of Medicine)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Lead Research Technologist – Translational Prostate Cancer Research Program (Cleveland Clinic)

Project Scientist – Prostate Cancer Research (University of California at Los Angeles)

Postdoctoral Position – Cancer Biology and Chemotherapy Resistance (Dalhousie University)

Postdoctoral Fellow – Drug Discovery/GU Oncology (Moffitt Cancer Center & Research Institute)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us